A Randomised, Placebo-controlled, Blinded, Cross-over, Pilot Study to Explore Safety and Efficacy of NBMI Treatment of Patients With Mild, Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 08 Mar 2021
At a glance
- Drugs Emeramide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors EmeraMed Limited
- 25 Jul 2018 Status changed to completed.
- 14 Sep 2016 New trial record